Celldex Therapeutics Inc (Celldex) is a biopharmaceutical company that develops and commercializes immunotherapeutics and vaccines for the treatment of several types of cancer. The company mainly focuses on using complementary technologies to develop a pipeline of immunotherapeutics comprised of therapeutic antibodies, antibody drug conjugates (ADCs), immune system modulators and vaccines. The company classifies its business into one segment, namely, development, manufacturing, and commercialization of novel therapeutics for human health care.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Celldex focuses its research and development efforts on advancing its drug candidates through clinical development. The company is actively developing Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potentlyr inhibits its activity. This is being studied across multiple mast cell driven diseases such as Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitist. Through its next generation bispecific antibody platform, the company intends to expand to additional candidates for inflammatory diseases and oncology. These targets are selected by the company based on new science as well as their compatibility to be used in bispecific antibody formats with its existing antibody programs. It has research laboratories located in Needham, massachusetts; Hampton, New Jersey; and New Haven, Connecticut. In FY2022, Celldex spent USS$82.3 million on its R&D activities, which grew 54.3% YoY.